Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Artery Diseases, Peripheral Clear all
Terminated Phase 3 Interventional

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059644
View directory record Official record
Conditions
Peripheral Vascular Disease
Interventions
Ecraprost in lipid emulsion
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
40 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Comorbidity Screening and Referral by Prosthetists

NCT05410548
View directory record Official record
Conditions
Limb Ischemia, Low Back Pain, Depression, Neuropathy;Peripheral, Amputation
Interventions
Standard-of-Care, Clinical Screening
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 15, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants

NCT07619885
View directory record Official record
Conditions
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
Interventions
CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
Drug
Lead sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries

NCT02522884
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Tack Endovascular System
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Yuma, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)

NCT04663867
View directory record Official record
Conditions
Peripheral Artery Occlusion, Peripheral Arterial Disease
Interventions
AngioSafe Peripheral CTO Crossing System
Device
Lead sponsor
AngioSafe, Inc.
Industry
Eligibility
22 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Chandler, Arizona • St. Helena, California • Darien, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparing BlueDop Vascular Expert to Ankle-Brachial Index in the Identification of Peripheral Vascular Disease

NCT06436001
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Dakota Vascular
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 15, 2026, 6:51 AM EDT
Completed No phase listed Observational

FLEX Arteriovenous Access Registry

NCT04070365
View directory record Official record
Conditions
Peripheral Artery Disease, Arteriovenous Fistula Stenosis, Arteriovenous Graft Stenosis
Interventions
FLEX Vessel Prep System followed by angioplasty
Device
Lead sponsor
VentureMed Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscaloosa, Alabama + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Natural Vascular Scaffold (NVS) Therapy

NCT03148808
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases, Catheterization, Peripheral
Interventions
NVS Therapy
Combination Product
Lead sponsor
Alucent Biomedical
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Columbus, Ohio • Wynnewood, Pennsylvania • Kingsport, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Detour2 Continued Access Study

NCT04625660
View directory record Official record
Conditions
Peripheral Artery Diseases
Interventions
PQ Bypass System
Device
Lead sponsor
Endologix
Industry
Eligibility
18 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Old Saybrook, Connecticut • Elk Grove Village, Illinois • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 15, 2026, 6:51 AM EDT
Completed No phase listed Observational

A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

NCT02974179
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Subjects from Study AG-CLI-0206 who received AMG0001
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional

FORMAT Clinical Study

NCT01804088
View directory record Official record
Conditions
Symptomatic Vascular Disease of the Iliac Arteries
Interventions
Formula™ 535 Iliac Balloon-Expandable Stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
12
States / cities
La Jolla, California • Bradenton, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

NCT03241459
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
Interventions
Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
Device
Lead sponsor
SurModics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 15, 2026, 6:51 AM EDT
Active, not recruiting Not applicable Interventional

First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease

NCT06410313
View directory record Official record
Conditions
Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
Interventions
ChampioNIR Ridaforolimus Eluting Peripheral Stent System
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 3 Interventional

Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study)

NCT00895635
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Diseases
Interventions
Treadmill Exercise Training, Arm Ergometry Exercise Training, Usual Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 15, 2026, 6:51 AM EDT
Not listed Phase 4 Interventional

Colonoscopy and Antiplatelet Therapy Trial

NCT06613191
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Peripheral Vascular Disease
Interventions
Aspirin, P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 15, 2026, 6:51 AM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease

NCT00380185
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
1,789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 15, 2026, 6:51 AM EDT
Recruiting No phase listed Observational

Diabetic Neuropathy in Spinal Cord Stimulator Patients

NCT04687215
View directory record Official record
Conditions
Diabetes Mellitus, Neuropathy, Neuropathic Pain, Vascular Diseases, Vascular Stiffness, Microvascular Changes, Pain, Chronic
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

NCT01157143
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
XRP0038 (NV1FGF)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 5, 2010 · Synced Oct 15, 2026, 6:51 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Surprise, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

NCT03480321
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol 100 mg, PMR 150 mg, PMR 200 mg
Drug
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Industry
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Clinical Trial Evaluating Negative Pressure Therapy to Decrease Vascular Groin Incision Complications

NCT02581904
View directory record Official record
Conditions
Wound Infection, Peripheral Arterial Disease, Aneurysm, Surgical Wound Dehiscence
Interventions
Prevena Care, Dry gauze dressing care
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 100 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study

NCT00228384
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
GORE VIABAHN Endoprosthesis, Bare Nitinol Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 15, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

NCT02956993
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
vonapanitase, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Long Beach, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 15, 2026, 6:51 AM EDT